UnknownPhase 4

Safety of Ertapenem in Beta-lactam Allergic Patients.

Italy30 participantsStarted 2011-01

Plain-language summary

The purpose of this study is to assess cross-reactivity and tolerability of ertapenem in patients with IgE-mediated allergy to at least one beta-lactam molecule.

Who can participate

Age range16 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * IgE-mediated allergy to at least one beta-lactam molecule Exclusion Criteria: * positive allergy testing to ertapenem * chronic diseases * treatment with beta-blockers * pregnancy

What they're measuring

Cross-reactivity between beta-lactams and ertapenem.

Timeframe: 1 day

Trial details

NCT IDNCT01159379

SponsorCatholic University of the Sacred Heart

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-09

Contact for this trial

Domenico Schiavino, MD

0630155896 dschiavino@rm.unicatt.it

View on ClinicalTrials.gov More IgE-Mediated Hypersensitivity trials